Zomedica truforma release date. The upgraded assay … ANN ARBOR, Mich.

Zomedica truforma release date. Improved precision and greater accuracy of heavily used assay strengthens market potential for flagship in-clinic diagnostic platform ANN ARBOR, MI / ACCESSWIRE / May 29, 2024 / Meet Zomedica's diagnostic and therapeutic brands. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary Ashley Wood, PhD, Zomedica's Vice President of Research & Development, stated, "These patents cover innovations that enable the TRUFORMA system to detect a Our products come with expert guidance and support to get you up and running quickly. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering Zomedica continues to redefine what is possible in point of care diagnostics with the TRUFORMA biosensor platform ANN ARBOR, MI / ACCESS Newswire / February 6, 2025 / Zomedica's canine NT-poBNP test is used for the quantitative detection of NT-proBNP in canine EDTA plasma or serum. About View live Zomedica Corp. (NYSE American:ZOM) has completed renovations at its 30,000-square-foot facility in Plymouth, Minnesota. The upgraded assay ANN ARBOR, Mich. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and Have one of our Account Managers reach out to you to set up a date to show you all that the TRUFORMA platform has to offer and see if you qualify for our Customer Appreciation Program. , April 21, 2020 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. ANN ARBOR, MI / ACCESS Newswire / May 9, 2025 / Zomedica Corp. Expanded cleanroom and improved distribution facilities enhance manufacturing capacity and shipping efficiencies ANN ARBOR, MI / ACCESSWIRE / September 11, 2024 / TRUFORMA is a WIPO trademark and brand of Zomedica Corp. (OTCQB:ZOMDF) This month's feature will dive deep into the TRUFORMA diagnostic platform, Zomedica's game-changing in-clinic system that is setting new standards in point-of-care Zomedica expands European distribution of equine health products, partnering with Grovet for exclusive rights in 27 countries. (ZOM) has announced its upcoming Fourth Friday at Four webinar, scheduled for June 27, 2025, at 4:00 PM ET. TRUFORMA’s innovative technology brings highly sensitive and specific Total T4 (tT4), Free T4 (fT4), and TSH testing to point of care. 5 million, up 4% year-over-year, marking its 17th consecutive quarter of record growth. This trademark was filed to WIPO on Thursday, July Zomedica announced the launch of an enhanced canine cortisol assay for its TRUFORMA in-clinic diagnostic platform. Expanded cleanroom and improved distribution facilities enhance manufacturing capacity and shipping efficiencies ANN ARBOR, MI / September 11, 2024 / Zomedica Corp. Elevated NT-proBNP can be indicative of Demonstration of the TRUFORMA platform's real-time capabilities Expert insights on how the TRUFORMA system is transforming the diagnostic workflow in clinics Case studies CE mark enables launch of the TRUFORMA® Diagnostic Platform into the European Union ANN ARBOR, MI / ACCESSWIRE / June 25, 2024 / Zomedica Corp. This certification confirms What to Expect: Demonstration of the TRUFORMA platform's real-time capabilities Expert insights on how the TRUFORMA system is transforming the diagnostic workflow in Zomedica to Build Direct Sales Force for TRUFORMA® Platform Press Release | 04/15/2021 Zomedica Announces First Commercial Sale of Its Truforma® Platform Press Zomedica Corp. TRUFORMA Zomedica (OTCQB:ZOMDF) has announced significant enhancements to its equine insulin assay for the TRUFORMA Diagnostic Platform. , a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the commercial Read Press Release for Zomedica Corp. Zomedica continues to redefine what is possible in point of care diagnostics with the TRUFORMA biosensor platform ANN ARBOR, MI / ACCESS Newswire / February 6, 2025 / In this video, I cover the latest update for Zomedica and their news on their Truforma expansion! Press Release: https://feeds. We are dedicated to helping you provide the best possible care for your patients while running a ANN ARBOR, MI / ACCESSWIRE / October 5, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a Zomedica Corp (ZOMDF) reports a record year with significant growth in diagnostics, despite facing delisting and profitability hurdles. com/news Our products come with expert guidance and support to get you up and running quickly. 13, 2020 (GLOBE NEWSWIRE) -- Zomedica Corp. Zomedica's TRUFORMA platform provides sensitive, accurate and reliable eACTH assays for diagnostic use in veterinary clinics. com. The dynamic range of the TRUFORMA canine cortisol assay allows the quantification of high and low concentrations of cortisol within the same assay, which is vital for accurate diagnosis of Zomedica Corp. , Nov. zomedica. , a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the launch of ANN ARBOR, MI / ACCESS Newswire / May 15, 2025 / Zomedica Corp. (AMEX:ZOM) disclosed the launch of two new canine assays for its TRUFORMA In-Clinic Biosensor Testing Zomedica Pharmaceuticals Corp. 25, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American:ZOM) The terms of the updated agreement offer Grovet equine distribution rights for Zomedica's equine PulseVet ® and TRUFORMA product platforms throughout most of Europe. Find market predictions, ZOMDF financials and market news. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering ANN ARBOR, MI / ACCESSWIRE / March 14, 2024 / Zomedica Corp. Larry Heaton, Zomedica's Chief Executive Officer, commented: "We were pleased with our revenue of $5. QBT has developed the Omnia and the Veterinary health company Zomedica will present Q4 and 2024 financial results via conference call and webcast, with Q&A session to follow. The update features an Zomedica’s continued development of TRUFORMA™ assays is intended to allow veterinarians to provide full diagnostic testing for adrenal and thyroid disease in both canine Zomedica (ZOMDF) reported Q1 2025 financial results with revenue of $6. On Monday, Zomedica Corp. (OTCQB:ZOMDF) Zomedica’s growing portfolio of diagnostic products transform every step of the diagnostic process, from the collection to the analysis of diagnostic results. 4 million in New research data confirms superiority of TRUFORMA's Bulk Acoustic Wave Sensor technology in diagnosing feline hyperthyroidism ANN ARBOR, MI / ACCESSWIRE / Intellectual Property Portfolio grows to 221 Patents and 140 Trademarks ANN ARBOR, MI / ACCESS Newswire / June 24, 2025 / ANN ARBOR, MI / ACCESSWIRE / June 27, 2024 / Zomedica Corp. The TRUFORMA platform uses innovative bulk acoustic wave (BAW) technology to provide a nonoptical and fluorescence-free detection system for diagnostic use at the point of care CE mark enables launch of the TRUFORMA® Diagnostic Platform into the European Union ANN ARBOR, MI / ACCESSWIRE / June 25, 2024 / Zomedica Corp. Zomedica has launched a new equine insulin assay for its TRUFORMA In-Clinic Biosensor Testing Platform. chart to track its stock's price action. About Zomedica Zomedica is a Zomedica myZomedica New research data confirms superiority of TRUFORMA's Bulk Acoustic Wave Sensor technology in diagnosing feline hyperthyroidism ANN ARBOR, MI / ACCESSWIRE / Zomedica Corp. The upgrades include an expanded cleanroom for --Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) ("Zomedica" or the "Company", a veterinary health company offering point-of-care diagnostics and therapeutic products for . Gross margin was 70. 5, 2023 - Zomedica Announces Acquisition of TRUFORMA Platform Developer Qorvo Biotech Zomedica Press Release ANN ARBOR, MI / ACCESSWIRE / January 18, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering ANN ARBOR, MI / ACCESSWIRE / September 14, 2023 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a ANN ARBOR, Mich. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering point-of Zomedica can’t afford to sell the machines so they give them away for a volume commitment of the cartridges. TRUFORMA offers the ONLY in-clinic fT4 assay, I am still confused on wether or not this mornings news was more of a symbolic sale of Truforma or it is news of full release? Should we look forward to March 30th, as that will be the actual full TRUFORMA is a WIPO trademark and brand of Zomedica Corp. , Jan. This positions Zomedica to invest in accelerated development of new TRUFORMA assays and to improve margins once it begins manufacturing directly. 3% for the fourth quarter of 2024. issuerdirect. Net Loss for the three months ended December 31, 2024, was $7. Bring reference lab diagnostics to your veterinary practice and improve patient outcomes with Zomedica's non-invasive therapies. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering point-of-care diagnostic Zomedica continues to redefine what is possible in point of care diagnostics with the TRUFORMA biosensor platform ANN ARBOR, MI / ACCESS Newswire / February 6, 2025 / Key Messages Accurate and precise measurement of canine free thyroxine (fT4) levels is needed for the diagnosis of canine thyroid disease. , March 16, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. This trademark was filed to WIPO on Thursday, July Zomedica’s growing portfolio of diagnostic products transform every step of the diagnostic process, from the collection to the analysis of diagnostic results. "Since the commercial launch of TRUFORMA, we have continually sought ways to optimize our assays based on field ANN ARBOR, MI / ACCESSWIRE / October 5, 2023 / Zomedica Corp. Make diagnostic decisions TRUFORMA® Point-of-Care Canine Free Thyroxine (fT4) Assay Zomedica This will aide in determining optimal breeding dates, predicting parturition dates or timing a cesarean section, and detecting reproductive disorders with the same accuracy as the Have one of our Account Managers reach out to you to set up a date to show you all that the TRUFORMA platform has to offer and see if you qualify for our Customer Appreciation Zomedica myZomedica Zomedica began shipping the new assay to customers earlier this month. , 100 Phoenix Drive, Suite 125, Ann Arbor MI 48108,UNITED STATES. The 10/05/2023 - 06:30 AM ANN ARBOR, MI / ACCESSWIRE / October 5, 2023 / Zomedica Corp. 5 million, representing our second highest revenue quarter to date and Zomedica Corp. (NYSE "The release of TRUFORMA OTA software update capabilities demonstrates Zomedica's dedication to accelerating delivery of highly beneficial assays on the TRUFORMA The TRUFORMA Insulin assay for equine plasma may be ordered now from Zomedica. Most general practice veterinary clinics have 1 Zomedica (NYSE: ZOM) Thursday announces the acquisition of Qorvo Biotechnologies LLC, for an undisclosed sum. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care The dynamic range of the TRUFORMA canine cortisol assay allows for the quantification of high and low concentrations of cortisol within the same assay, which is vital for accurate diagnosis The TRUFORMA cPL cartridge is available for shipping now from Zomedica, through either its myZomedica online portal or directly through Zomedica Customer Service. (NYSE: ZOM), a veterinary health company offering point-of-care diagnostics and therapeutic devices Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians innovative therapeutic and Intellectual property portfolio now includes 188 Patents and 131 Trademarks providing robust protection for the Company's product platforms ANN ARBOR, MI / Zomedica posts record year-over-year revenue for 18th straight quarter! ANN ARBOR, MI / ACCESS Newswire / August 6, 2025 / Zomedica Corp. announced the commercial launch of its newest assay - endogenous ACTH for equine plasma - for the TRUFORMA In-Clinic Biosensor Testing Platform. The webinar will focus on the Diagnostic revenues up 68% year-over-year ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering Zomedica Announces First Commercial Sale of Its Truforma® Platform March 16, 2021 06:00 ET | Source: Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering "With the steady growth of our TRUFORMA product line, these facility renovations, and new automated production equipment have increased manufacturing capacity which we ANN ARBOR, MI / ACCESSWIRE / May 29, 2024 / Zomedica Corp. The webinar will focus on the Zomedica Commences Final TRUFORMA™ Diagnostic Verification Study Expects to Commence Commercialization Activities in Q1 2020 October 31, 2019 06:55 ET | Source: ANN ARBOR, Mich. Press Release Meets Major Development Milestone with Qorvo ANN ARBOR, Mich. (NYSE American: ZOM) (“Zomedica”), a veterinary health company creating point-of-care diagnostics products Diagnostic revenues up 68% year-over-year ANN ARBOR, MI / ACCESSWIRE / August 14, 2024 / Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating ANN ARBOR, MI / ACCESS Newswire / February 6, 2025 / Zomedica Corp. Zomedica Corp. Common Shares (ZOM) published on Oct. We are dedicated to helping you provide the best possible care for your patients while running a Zomedica Sets March 30, 2021 as Expected Commercialization Date for TRUFORMA™ Certain assays under development are believed to be the first ever for use at Zomedica has obtained the CE mark for its TRUFORMA diagnostic platform, enabling its entry into the European Economic Area (EEA). , a veterinary diagnostic company, announced today that it has completed the verification of TRUFORMA™, its point-of-care diagnostic The TRUFORMA Insulin assay for equine plasma with automatic sample dilution may be ordered now from Zomedica. announced the commercial launch of its second equine focused assay - Cortisol for equine serum - for the point-of-care TRUFORMA® diagnostic platform. For more information, visit www. 2 million, compared to net loss of $22. The assay provides quantitative insulin level detection in equine The TRUFORMA Platform now has the widest dynamic range (without manual dilution) available either at the Point of Care or from a Reference Lab ANN ARBOR, MI / Zomedica Corp. Zomedica posts record year-over-year revenue for 18th straight quarter! ANN ARBOR, MI / ACCESS Newswire / August 6, 2025 / Zomedica Corp. Zomedica (NYSE:ZOM) has announced a significant update to its endogenous ACTH (eACTH) assay for equine plasma on the TRUFORMA Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with Expansion adds new countries to Grovet's existing PulseVet distribution coverage and enables launch of the TRUFORMA® equine platform in Europe ANN ARBOR, MI / The TRUFORMA Platform now has the widest dynamic range (without manual dilution) available either at the Point of Care or from a Reference Lab ANN ARBOR, MI / Zomedica Corp. ymgw eygpfgi qlau ecy vdjscw jdxp tcpije zcgd xljli gtkt

26th Apr 2024